Providence Wealth Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.74M | Buy |
12,779
+115
| +0.9% | +$25.5K | 1.74% | 15 |
|
|
2025
Q4 | $2.77M | Buy |
12,664
+26
| +0.2% | +$5.92K | 1.73% | 17 |
|
|
2025
Q3 | $2.88M | Buy |
12,638
+54
| +0.4% | +$11K | 1.81% | 14 |
|
|
2025
Q2 | $2.5M | Sell |
12,584
-486
| -4% | -$90.3K | 1.72% | 16 |
|
|
2025
Q1 | $2.7M | Buy |
13,070
+43
| +0.3% | +$8.36K | 2.04% | 15 |
|
|
2024
Q4 | $2.35M | Buy |
13,027
+22
| +0.2% | +$4.04K | 1.78% | 15 |
|
|
2024
Q3 | $2.44M | Sell |
13,005
-349
| -3% | -$65.1K | 1.81% | 16 |
|
|
2024
Q2 | $2.29M | Buy |
13,354
+188
| +1% | +$31.1K | 1.83% | 13 |
|
|
2024
Q1 | $2.38M | Buy |
13,166
+8,456
| +180% | +$1.46M | 2.03% | 14 |
|
|
2023
Q4 | $535K | Sell |
4,710
-8,244
| -64% | -$1.2M | 0.48% | 56 |
|
|
2023
Q3 | $1.91M | Sell |
12,954
-409
| -3% | -$60K | 2.13% | 12 |
|
|
2023
Q2 | $1.84M | Sell |
13,363
-597
| -4% | -$87.5K | 2.04% | 11 |
|
|
2023
Q1 | $2.25M | Sell |
13,960
-407
| -3% | -$62.2K | 1.66% | 16 |
|
|
2022
Q4 | $2.35M | Buy |
14,367
+177
| +1% | +$27.1K | 1.74% | 17 |
|
|
2022
Q3 | $2.13M | Buy |
14,190
+609
| +4% | +$87.4K | 1.59% | 19 |
|
|
2022
Q2 | $2.06M | Buy |
13,581
+992
| +8% | +$152K | 1.49% | 21 |
|
|
2022
Q1 | $2.05M | Sell |
12,589
-937
| -7% | -$136K | 1.32% | 23 |
|
|
2021
Q4 | $1.83M | Buy |
13,526
+2,009
| +17% | +$237K | 1.15% | 29 |
|
|
2021
Q3 | $1.25M | Sell |
11,517
-1,127
| -9% | -$129K | 0.87% | 38 |
|
|
2021
Q2 | $1.46M | Buy |
12,644
+134
| +1% | +$15.1K | 0.99% | 32 |
|
|
2021
Q1 | $1.35M | Buy |
12,510
+963
| +8% | +$103K | 0.99% | 35 |
|
|
2020
Q4 | $1.22M | Buy |
11,547
+1,214
| +12% | +$117K | 1.01% | 33 |
|
|
2020
Q3 | $905K | Buy |
10,333
+4,628
| +81% | +$436K | 0.89% | 39 |
|
|
2020
Q2 | $560K | Buy |
5,705
+2,054
| +56% | +$181K | 0.57% | 55 |
|
|
2020
Q1 | $265K | Buy |
3,651
+134
| +4% | +$11.4K | 0.32% | 70 |
|
|
2019
Q4 | $311K | Buy |
3,517
+8
| +0.2% | +$664 | 0.29% | 70 |
|
|
2019
Q3 | $266K | Buy |
+3,509
| New | +$241K | 0.24% | 77 |
|
|
2019
Q2 | – | Sell |
-3,277
| Closed | -$263K | – | 76 |
|
|
2019
Q1 | $263K | Buy |
3,277
+6
| +0.2% | +$491 | 0.25% | 75 |
|
|
2018
Q4 | $298K | Sell |
3,271
-295
| -8% | -$25.9K | 0.33% | 67 |
|
|
2018
Q3 | $337K | Buy |
3,566
+5
| +0.1% | +$474 | 0.31% | 68 |
|
|
2018
Q2 | $330K | Buy |
3,561
+255
| +8% | +$24.9K | 0.32% | 71 |
|
|
2018
Q1 | $302K | Buy |
+3,306
| New | +$363K | 0.45% | 54 |
|
Other funds holding ABBV
VCM
VPM
Providence Wealth Advisors's ABBV Position: Q1 2026 in Review
Providence Wealth Advisors increased its AbbVie (ABBV) stake by 0.91% in Q1 2026, buying an estimated $25.5K and bringing the position to 12,779 shares worth $2.74M. The position accounts for 1.74% of the portfolio, ranked #15.
Providence Wealth Advisors first reported a position in ABBV in Q1 2018 and has held it in 32 quarters since. The position peaked at $2.88M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Providence Wealth Advisors held 12,779 shares of AbbVie worth $2.74M as of Q1 2026.
- Providence Wealth Advisors bought 115 AbbVie shares in Q1 2026, an estimated $25.5K.
- AbbVie made up 1.74% of Providence Wealth Advisors's portfolio in Q1 2026, its #15 holding.
- Providence Wealth Advisors first reported a position in AbbVie in Q1 2018 and has held it in 32 quarters since.
- Providence Wealth Advisors's AbbVie position peaked at $2.88M in Q3 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Providence Wealth Advisors's 13F filing for Q1 2026, filed 5 May 2026.